Impact of renal-adjusted ceftazidime/avibactam in patients with KPC-producing bloodstream infection: a retrospective cohort study.

Background: Bloodstream infections (BSIs) caused by KPC-producing (KPC-Kp) are still associated with high mortality, and the game-changing drug ceftazidime/avibactam has shown suboptimal pharmacokinetics in some clinical settings. Ceftazidime/avibactam renal dose adjustment has recently been identified as an independent risk factor for mortality.

Objectives: To investigate the effect of ceftazidime/avibactam renal dose adjustment on mortality.

[Alkaline phosphatase isoenzymes in a case of transient hyperphosphatasemia].

Authors reports the case of a seven months toddler with transient hyperphosphatasemia without clinical manifestations and no other hepatic or bone disfunctions. Resolution of both enzymes and bone isoenzymes occurs within 5 months.